References
- Giusti B , GoriAM, MarcucciR, AbbateR. Current status of clopidogrel pharmacogenomics. Pharmacogenomics13(15) , 1671–1674 (2012).
- Nguyen TA , DiodatiJG, PharandC. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol.45(8) , 1157–1164 (2005).
- Giusti B , GoriAM, MarcucciR, SaraciniC, VestriniA, AbbateR. Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers. Med.3 , 33–50 (2010).
- Salleh MZ , TehLK, LeeLS et al. Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalised medicine. PLoS ONE 8(8) , e71554 (2013).
- Thomson VS , JohnB, PatiPK, GeorgeOK, GeorgePV, JoseJ. Nonresponders to clopidogrel therapy among Indian patients undergoing elective/adhoc angioplasty. Indian Heart J.60(6) , 543–547 (2008).
- Kumar S , SaranRK, PuriA et al. Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome. Indian Heart J. 59(2) , 152–156 (2007).
- Chan MY , TanK, TanHC et al. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics13(5) , 533–542 (2012).
- Tabassum R , ChauhanG, DwivediOP et al. Genome-wide association study for Type 2 diabetes in Indians identifies a new susceptibility locus at 2q21. Diabetes 62(3) , 977–986 (2013).
- Indian Diabetes Consortium. INDICO: the development of a resource for epigenomic study of Indians undergoing socioeconomic transition. Hugo J.5(1–4) , 65–69 (2011).
- Dahl ML , GunesA. Implications of inter-individual differences in clopidogrel metabolism, with focus on pharmacogenetics. Pharmaceuticals3(4) , 782–794 (2010).
- Davi G , PatronoC. Platelet activation and atherothrombosis. N. Engl. J. Med.357(24) , 2482–2494 (2007).
- Mehta SR , YusufS, PetersRJ et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281) , 527–533 (2001).
- Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8) , 849–857 (2009).
- Shahabi P , SiestG, Visvikis-SiestS. Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin. Pharmacogenomics13(11) , 1215–1218 (2012).
- Collet JP , Ten Berg JM. ARCTIC-GENE: clopidogrel monitoring failed to improve outcomes. ESC Congress2013 , 711 (2013). www.escardio.org/congresses/esc-2013/congress-reports/Pages/711-ARCTIC-GENE.aspx#.Ux04rfQW2xU
- Mega JL , SimonT, ColletJP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16) , 1821–1830 (2010).
- Taubert D , von Beckerath N, Grimberg G et al. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther.80(5) , 486–501 (2006).
- Mega JL , CloseSL, WiviottSD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749) , 1312–1319 (2010).
- Shalia KK , ShahVK, PawarP, DivekarSS, PayannavarS. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response. Indian Heart J.65(2) , 158–167 (2013).
- Balram C , SharmaA, SivathasanC, LeeEJ. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br. J. Clin. Pharmacol.56(1) , 78–83 (2003).
- Bravo-Villalta HV , YamamotoK, NakamuraK, BayaA, OkadaY, HoriuchiR. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur. J. Clin. Pharmacol.61(3) , 179–184 (2005).
- Mega JL , CloseSL, WiviottSD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4) , 354–362 (2009).
- Adithan C , GerardN, VasuS, RosemaryJ, ShashindranCH, KrishnamoorthyR. Allele and genotype frequency of CYP2C19 in a Tamilian population. Br. J. Clin. Pharmacol.56(3) , 331–333 (2003).
- Jose R , ChandrasekaranA, SamSS et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam. Clin. Pharmacol.19(1) , 101–105 (2005).
- Harmsze AM , van Werkum JW, ten Berg JM et al.CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control study. Eur. Heart J.31(24) , 3046–3053 (2010).
- Suh JW , KooBK, ZhangSY et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174(12) , 1715–1722 (2006).
- Bouman HJ , SchomigE, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med.17(1) , 110–116 (2011).
- Hulot JS , ColletJP, CaylaG et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ. Cardiovasc. Interv.4(5) , 422–428 (2011).
- Sangkuhl K , ShuldinerAR, KleinTE, AltmanRB. Platelet aggregation pathway. Pharmacogenet. Genomics21(8) , 516–521 (2011).
- Kar R , MeenaA, YadavBK, YadavR, KarSS, SaxenaR. Clopidogrel resistance in north Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets24(4) , 297–302 (2013).
- Cattaneo M . Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol.24(11) , 1980–1987 (2004).
- Patowary A , PurkantiR, SinghM et al. Systematic analysis and functional annotation of variations in the genome of an Indian individual. Hum. Mutat. 33(7) , 1133–1140 (2012).